Symposia: Aggressive Lymphomas: Clinical and Epidemiological
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Biological therapies, adult, epidemiology, Lymphomas, non-Hodgkin lymphoma, Bispecific Antibody Therapy, Clinical Practice (Health Services and Quality), Non-Biological therapies, Clinical Research, B Cell lymphoma, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Combination therapy, health outcomes research, Checkpoint Inhibitor, Diseases, real-world evidence, aggressive lymphoma, Therapies, Immunotherapy, registries, Lymphoid Malignancies, Adverse Events, Study Population, Human, Radiation Therapy
Type: Oral
Hematology Disease Topics & Pathways:
Research, Biological therapies, adult, epidemiology, Lymphomas, non-Hodgkin lymphoma, Bispecific Antibody Therapy, Clinical Practice (Health Services and Quality), Non-Biological therapies, Clinical Research, B Cell lymphoma, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Combination therapy, health outcomes research, Checkpoint Inhibitor, Diseases, real-world evidence, aggressive lymphoma, Therapies, Immunotherapy, registries, Lymphoid Malignancies, Adverse Events, Study Population, Human, Radiation Therapy
Sunday, December 11, 2022: 12:00 PM-1:30 PM
R02-R05
(Ernest N. Morial Convention Center)
Moderators:
Tarec Christoffer El-Galaly, MD, DSc, Department of Haematology, Aalborg University Hospital
and
Juan Pablo Alderuccio, MD, University of Miami Miller School of Medicine
Disclosures:
El-Galaly: Abbvie: Other: Teaching in 2021; Roche: Ended employment in the past 24 months. Alderuccio: ADC Therapeutics: Consultancy, Research Funding; Pyramid: Consultancy; Agios: Consultancy.
This session provides real world data on clinical features, treatment patterns, and outcomes for patients with aggressive B-cell NHL who are refractory to or relapse after CAR T–cell therapy. In addition, this session provides relevant population-based data to guide prognostication, staging, risk assessment, and treatment of CNS lymphoma.
12:00 PM
12:15 PM
12:30 PM
12:45 PM
1:00 PM
1:15 PM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH